The AR (androgen receptor) is a ligand-activated transcription factor that mediates the action of the steroids testosterone and dihydrotestosterone. Alterations in the AR gene result in a number of clinical disorders, including: androgen-insensitivity, which leads to disruption of male development; prostate cancer; and a neuromuscular degenerative condition termed spinal bulbar muscular atrophy or Kennedy's disease. The AR gene is X-linked and the protein is coded for by eight exons, giving rise to a C-terminal LBD (ligand-binding domain; exons 4-8), linked by a hinge region (exon 4) to a Zn-finger DBD (DNA-binding domain; exons 2 and 3) and a large structurally distinct NTD (N-terminal domain; exon 1). Identification and characterization of mutations found in prostate cancer and Kennedy's disease patients have revealed the importance of structural dynamics in the mechanisms of action of receptors. Recent results from our laboratory studying genetic changes in the LBD and the structurally flexible NTD will be discussed.
Introduction
The AR (androgen receptor) is thought to be the sole mediator of the actions of the steroid hormones testosterone and DHT (dihydrotestosterone) in male reproductive tissues, such as the testes, epididymus and prostate, and non-reproductive tissues such as muscle and bone. AR is a member of the nuclear receptor superfamily, and is organized into discrete structural and functional domains ( Figure 1 ). The C-terminal LBD (ligand-binding domain) and the central DBD (DNA-binding domain) show significant identity both between ARs of different species and with other members of the nuclear receptor superfamily (see [1] and references cited therein). In contrast, the NTD (N-terminal domain) of the protein is more divergent, and is characterized by homopolymer tracts of glutamine, glycine and proline residues (see [1] [2] [3] and references cited therein). Regions within the Nterminus of the human and rat receptors that are important for transactivation, collectively termed AF1 (activation function 1), participate in multiple protein-protein interactions with general transcription factors and co-regulatory proteins (reviewed in [4] ). The AF1 domain is structurally flexible and has the propensity to form an α-helix structure in the presence of a target protein or an organic osmolyte [5, 6] .
Western world. In 2000, it was the most commonly diagnosed cancer in men in the U.K. [7] . Androgen signalling is necessary for normal growth and differentiation of the prostate gland and is also important for tumour growth (reviewed in [8] ). Thus treatment primarily involves targeting the androgen signalling pathway by blocking production of testicular androgens and inhibiting AR function. Although initially such treatments are successful in managing the disease, the period of remission is variable and inevitably the tumour escapes this androgen ablation therapy and progresses to a hormone-independent state with concomitant poor prognosis. However, the hormone-resistant tumours still retain a functional AR and progression may be associated with amplification of the receptor gene and/or mutations of the receptor protein (reviewed in [9] ). Such changes in receptor levels or structure/function are likely to confer selective advantage on the tumour cells in the low androgen milieu associated with androgen ablation therapy.
Point mutations in the LBD
The LBD is important for steroid binding, dimerization and protein-protein interactions with co-regulatory proteins and has a globular conformation consisting of up to 12 α-helices in a three-layer sandwich (Figure 2A ). There are currently at least 28 crystal structures for the wild-type and different mutant AR-LBDs in the Entrez Structure database, with both the natural ligands testosterone and DHT as well as the synthetic agonist R1881, the anabolic steroid THG (tetrahydrogestrinone) and a number of non-steroidal ligands bound. There are also co-crystals with a number of hydrophobic motif ( XX , where is phenylalanine, leucine or tryptophan)-containing peptides bound to the AF2 surface. Most of the AR point mutations in prostate cancer have been The upper panel shows the domain organization of the receptor protein and the helical structure of the LBD and DBD. The structurally distinct NTD is shown schematically and the position of four tryptophan (W) residues and poly-amino acid repeats are highlighted: Q, glutamine; P, proline; A, alanine; and G, glycine. The AF1 transactivation function is also marked in yellow. Note that the structure(s) of the linker regions between the LBD and DBD and the DBD and NTD have not been solved. Middle panel: secondary structure predication for the whole AR: blue and red bars represent α-helix and β-strand respectively [28] .
Lower panel: prediction of natural disordered structure (PONDR R ; [29] ) for the AR protein. Scores above 0.5 represent regions of predicted natural disordered structure. The solid lines represents sequences highly predicted to be unstructured.
mapped to mutational hotspots in the LBD: amino acids 670-678, 701-730 and 874-919 [10] . The occurrence of point mutations in the AR and their role in prostate cancer tissue have been an area of intense research and some controversy. Although the identification of AR point mutations in prostate cancer patients has varied widely from 0 to 50% of tumours, there does appear to be a good correlation with anti-androgen treatment and the advanced stages of the disease and changes in the receptor protein, suggesting that receptor mutations are less important in the early stages of the disease (see [11] and references cited therein).
Characterization of the molecular phenotype of the AR point mutations in prostate cancer could have important implications for patient response to hormone therapy and the effectiveness of different treatment strategies. The availability of the crystal structure has allowed different point mutations to be mapped on to the structure and the consequences for AR function and structure to be predicted (Figure 2A ). Using a combination of cell culture (reporter gene and ligandbinding studies) and expression of wild-type and mutant AR-LBD polypeptides in Escherichia coli ( Figure 2D ) for biochemical studies, we have investigated a selection of mutations identified in prostate cancer patients.
A panel of mutations, identified in primary tumours (I672T, R726L, Q798E and H874Y) and/or metastatic disease (K720E, R726L, V757A, Q798E, T877A and D879G) with or without prior hormone therapy, was studied ( Figure 2A ). All mutations demonstrated activation of a reporter gene by testosterone and DHT, although I672T (helix 1), V757A (loop between helices 5 and 6) and Q798E (loop between helices 7 and 8) showed reduced activity relative to the wild-type receptor ( [11] ; J. Duff and I.J. McEwan, unpublished work). Mutations Q798E, H874Y (helix 10/11) and T877A (helix 10/11) also displayed altered ligand-binding specificity with non-androgenic steroids (progesterone, oestradiol and/or DHEA) and, in the case of the latter two mutations, non-steroidal anti-androgens were now able to activate a receptor-driven reporter gene ( [11] ; J. Duff and I.J. McEwan, unpublished work). Members of the p160 co-activator family {SRC1 (steroid receptor co-activator 1), SRC2 [TIF2 (transcriptional intermediary factor 2) or GRIP1 (glutamate receptor-interacting protein 1)] and SRC3 [ACTR (activator of thyroid and retinoid receptor), RAC3 (receptor-associated co-activator 3) or AIB1 (amplified in breast cancer-1)]} have been shown to interact with a hydrophobic pocket on the surface of the LBD via LXXLL motifs and to be stabilized by a charge clamp consisting of Lys 720 (helix 3) and Glu 897 (helix 12). These interactions are weaker for the AR-LBD, due to reduced hydrophobic interactions and loss of hydrogenbonding to the Glu 897 [12] . Thus, not surprisingly, mutations K720E and R726L both significantly disrupted p160 protein binding to the AR-LBD. However, p160 binding was also disrupted by V757A and impaired by Q798E, suggesting allosteric changes with the co-activator binding surface (J. Duff and I.J. McEwan, unpublished work). In contrast, H874Y demonstrated increased interactions with p160 family members and increased transcriptional activity in co-transfection studies [11] . The results with H874Y indicate that a combination of altered ligand-binding properties and enhanced binding to p160 co-activators may be responsible for the 'gain-of-function' of this point mutation and may suggest mechanisms leading to hormone-refractory disease. For the mutations Q798E and the well-studied T877A, the broadened spectrum of ligand-binding preference appears the main 'gain-of-function'. However, for the other mutations tested, the link between the receptor change and prostate cancer remains to be determined. Interestingly, Shi et al. [13] reported that some of the mutations studied here (I672T, R726L and D890N) exhibited some activity with the adrenal steroid DHEA in a yeast cell assay.
Generally, all the above mutants tested showed a similar sensitivity to limited trypsinization as the wild-type protein, with the exception of Q798E, which appeared to be more sensitive to digestion in both the absence and presence of DHT (J. Duff and I.J. McEwan, unpublished work). This suggests that this mutation may lead to structural alterations in the LBD or the adjacent hinge region. This mutation is interesting because the same change has been described in a patient with partial androgen-insensitivity (loss of AR function) as well as metastatic prostate cancer cells (presumed gain of function). His 874 is located within the C-terminus of helix 11 and is part of a highly conserved eight-aminoacid sequence L 873 HQFTFDL 880 that includes Thr 877 and Asp 879 , residues also mutated in prostate cancer (see [11] and references cited therein). The conserved nature of all three residues strongly suggests an important structural and/or functional role. Indeed T877A, which was originally identified in the LNCaP metastatic prostate cell line, has been shown in the crystal structure of the AR-LBD to play a role in the discrimination of the steroid D-ring ( Figure 2B ; see [11] and references cited therein). In contrast, His 874 (see Figure 2B ) and Asp 879 are not directly implicated in steroid binding from the LBD crystal structures. Using the DeepView/Swiss-PdbViewer program [14] , it is possible to model the consequences of changing this residue to a tyrosine. Figures 2(B) and 2(C) show sculpted views of the ligandbinding pocket, with DHT bound (PDB code 1T7T) for the wild-type histidine residue ( Figure 2B ) and the mutated tyrosine ( Figure 2C) 907 . It is possible that the steric clashes predicted for these positions could lead to a local disruption in the structure, creating a larger ligand-binding pocket that can accommodate non-androgenic steroids. Furthermore, such a rearrangement of these residues may alter the AF2 transactivation surface and explain the enhanced binding of p160 co-activators observed for this mutation [11] .
Kennedy's disease [SBMA (spinal bulbar muscular atrophy)]
Polymorphisms in the amino acid repeats located in the AR-NTD (Figure 1 ) have been associated, sometimes controversially, with a number of diseases including prostate cancer risk, male pattern baldness and infertility (reviewed in [2] ). Less controversial is the wealth of evidence revealing that expansion of the largest poly-Q repeat within the AR-NTD results in motor neurone cell death in the brain stem and spinal cord and leads to a progressive muscle wasting condition termed SBMA or Kennedy's disease (see [2] and references cited therein). Thus the AR is part of a growing list of proteins that cause neurodegenerative disease through the amplification of amino acid repeats [15] . Despite extensive research, the pathology of these diseases remains unclear [2, 15] . Studies from animal models and cell culture have suggested that fragmentation and/or changes in subcellular localization, together with aggregation, could all play a role in disease aetiology or progression. A consideration of protein sequences of the AR and other triplet disease proteins reveals that repeats prone to expansion have increased in size during evolution [16] , and thus it could be speculated that the repeat has a role to play in the normal function of the target protein in higher primates.
The AR-NTD is structurally flexible
We have previously reported on the location of putative secondary structure elements in the AR-AF1 transactivation domain (amino acids 142-485) [5] . We have also demonstrated that this region of the AR-NTD is structurally flexible and adopts a more stable conformation in the presence of structure-stabilizing agents and upon binding the target protein TFIIF (transcription factor IIF) [5, 6] . Indeed, interactions with the large subunit of TFIIF, RAP74 (RNA polymerase II-associating protein 74), lead to induced α-helix structure [6] . Figure 1 presents a schematic representation of the human AR with predicted secondary structure elements and regions of natural disordered structure. It is striking that in contrast with the DBD and the LBD, the NTD has more limited secondary structure and significant regions of natural disordered structure: the regions between amino acids 40 and 160, which includes the large poly-Q repeat, and 180 and 225 are strongly predicted to be disordered.
To date, limited information is available regarding the structural consequences of expansion or contraction of poly-Q repeats and this is derived mainly from studies with isolated peptides. Such studies have suggested variable conformations for the poly-Q peptide of different lengths and flanking amino acids, from non-ordered [17] [18] [19] , with a propensity to form α-helix in hydrophobic environment [17] , to β-strand [20, 21] structure. More recent structural studies of the ataxin-3 protein, responsible for Machado-Joseph disease, suggest that expansion of the polyglutamine repeat does not affect protein stability [22] and that the repeat is in a non-ordered conformation [23] . Clearly, to get a better understanding of the structure and function of poly-Q repeats, it will be important to study the repeat in the context of the target proteins. We have used biophysical and biochemical approaches to investigate the conformation of the AR-NTD with variable (0, 20 and 45) poly-Q repeat lengths. Similar to what we observed for the isolated AR-AF1 domain, the NTD has limited secondary structure in aqueous solution, but adopts a more α-helical conformation in the presence of the natural osmolyte TMAO (trimethylamine oxide) or the hydrophobic solvent trifluoroethanol. Differences in secondary structure content (CD spectra) were also observed for the three polypeptides with different poly-Q repeat lengths (P. Davies, K. Watt and I.J. McEwan, unpublished work). The tertiary folding of the AR-NTD was investigated by tryptophan fluorescence emission and sensitivity to partial proteolysis. These studies also revealed differences in structural folding and flexibility with respect to the poly-Q repeat length, and suggest that the repeat confers a structural flexibility on the AR-NTD and that expansion of the repeat causes regionlimited alterations rather than global changes in conformation (P. Davies, K. Watt and I.J. McEwan, unpublished work). Such alterations may play an important role in protein function (i.e. protein-protein interactions) and/or susceptibility to form insoluble aggregates in vivo.
Conclusions and future perspectives
In conclusion, we have shown that amino acid changes in the AR-LBD, notably H874Y, can be accommodated without dramatic alterations in the structure of the LBD, but the local changes in the region of the ligand-binding pocket/AF2 domain may be sufficient to permit a wider range of steroids and non-steroid ligands to act as agonists. In addition, we found that H874Y mutation led to enhanced co-activator interactions and transactivation activity. Either, or both, of these phenotypes would result in a more active AR and could contribute to the progression of tumours to an 'androgenindependent', receptor-dependent state. The findings also emphasize the importance of a highly conserved motif in helix 10/11 for selective hormone binding and co-activatordependent transactivation. Recent work from Wilson and coworkers [24] has also observed local structural changes as a consequence of point mutations in the LBD associated with androgen-insensitivity syndrome or prostate cancer [24] . Mutations were observed to alter ligand-binding stability (half-life) and protein-protein interactions.
The AR-NTD/AF1 is critical for receptor-dependent gene regulation and is involved in multiple protein-protein interactions with co-regulatory proteins and functionally binds to the LBD (reviewed in [3, 4] ). We have shown that the AF1 domain (amino acids 142-485) is structurally flexible, with limited secondary structure and possible regions of natural disorder, and undergoes induced folding and/or secondary structure rearrangements, resulting in a significant increase in α-helical structure upon protein-protein interactions or stabilization with TMAO, a natural osmolyte [5, 6] . We also observed that introducing point mutations into a six-aminoacid repeat (P 158 STLSL 163 ) within AR-AF1 was predicted to cause a β-stand to α-helix transition, and resulted in a more folded conformation and disruption of binding of the general transcription factor TFIIF [25] . Extending these structures to the intact NTD with different lengths of a poly-Q repeat (0, 20 and 45) further emphasized the flexible nature of this domain and revealed a role for poly-Q repeat in regulating structural dynamics. Interestingly, a point mutation in the NTD, associated with prostate cancer (E231G), was predicted to stabilize the structure of this domain [26] . Strikingly, the introduction of two leucine residues to disrupt the poly-Q repeat resulted in a theoretically more stable conformation and was observed to enhance transcriptional activity [27] . Taken together, these studies emphasize that local and/or global structural plasticity in the AR-NTD is critical for receptor function, and alterations in flexibility can lead to pathological receptor activity. Further, it appears that structural flexibility in the NTD of steroid receptors may represent a common property for these receptors that is important for the role of this domain in multiple protein-protein interactions and assembly of multiprotein transcription complexes (reviewed in [4] ). Investigation of the structural impact of genetic changes in the AR protein is likely to continue to provide critical information on the link between protein dynamics and plasticity and mechanism(s) of action.
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